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To the Editor:
Asthma is an inflammatory airway disorder profoundly
involving immune system and bronchial tissue function. The
FIG 1. Effect of CpG-2006 stimulation on ALI-cultured bronchial epithelial
cells. A, Left panel, Increased TER over time in healthy donor–derived bron-
chial epithelial cells at different concentrations of CpG-2006 treatment.
Right panel, Dose-dependent decrease in FITC-dextran paracellular perme-
ability across nonasthmatic epithelium treated with CpG-2006. CpG-2006
was added to cultures in the beginning of the experiment. B, TER (left
panel) and paracellular FITC-dextran permeability (right panel) of epithelial
cells from nonasthmatic subjects stimulated by IL-13 with or without
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inhaled allergens, dust particles, pollutants, or microorganisms.
Consequently, bronchial epithelial cells are at the forefront of
tissue defense and the innate immune response, preventing
invasion of tissues as a physical barrier. Tight junctions (TJs)
located at the most apical region of the lateral cell membrane seal
the epithelium and form an essential part of the barrier between
inner tissues and the external environment.1,2
Accumulating evidence has revealed dysfunction of the
bronchial epithelial barrier in asthmatic patients, as well as in
patients with atopic dermatitis and chronic rhinosinusitis.1,3,4 An
impaired barrier allows entry of inhaled substances into submuco-
sal tissues in higher quantities, whichmight lead to allergen sensi-
tization and induction of innate and adaptive immune responses.
In addition, activated immune cells release proinflammatory cyto-
kines that can further disrupt the epithelial barrier and result in
airway remodeling.1 It has been demonstrated that stimulation
with different proinflammatory factors, cytokines, and dust mite
or pollen extracts compromises the bronchial epithelial bar-
rier.1,5,6 Therefore barrier dysfunction appears to be a crucial
event in the initiation and chronicity of asthma.
We report that CpG-DNA, which is recognized by Toll-like
receptor (TLR) 9, enhances barrier function of bronchial
epithelial cells by increasing TJ molecule expression. First, we
investigated whether CpG-DNA (CpG-2006) could affect the
barrier integrity of bronchial epithelial cells. We stimulated air-
liquid interface (ALI) cultures of primary human bronchial
epithelial cells from nonasthmatic subjects with various concen-
trations of CpG-2006. Stimulation with 1 or 10 mmol/L CpG-
2006 constitutively increased transepithelial electric resistance
(TER; Fig 1, A, left panel). In parallel experiments paracellular
permeability, which was measured as diffusion of fluorescein
isothiocyanate (FITC)–conjugated 4-kDa dextran across the
epithelial layers, was decreased in a dose-dependent manner
(Fig 1, A, right panel). There was no difference observed between
apical and basolateral CpG administration (see Fig E1 in this
article’s Online Repository at www.jacionline.org). In addition,
other TLR9 ligands, CpG-K3 and CpG-K23, were also able to
increase barrier function (see Fig E2, A and B, in this article’s
Online Repository at www.jacionline.org). Control DNA, which
cannot activate TLR9, changed neither TER nor paracellular
permeability (see Fig E2,C). Collectively, these data demonstrate
that CpG-DNA can enhance the barrier integrity of healthy bron-
chial epithelial cells.
It was demonstrated previously that the TH2 response, particu-
larly when mediated by IL-4 and IL-13, can compromise the
bronchial and sinus epithelial barrier.1,4 Accordingly, we investi-
gated whether CpG-2006 can rescue IL-13–induced barrier
impairment. Consistent with previous studies, IL-13 decreased
and CpG-2006 increased barrier integrity in ALI cultures (Fig
1, B). Of interest, CpG-2006 treatment rescued the decrease in
IL-13–stimulated ALI-cultured bronchial epithelial cells (Fig 1,
B). However, when bronchial epithelial cells were pretreatedretreatment of CpG-2006. CpG-2006 or IL-13 was added at t 5 0 or
5 24, respectively. TER is compared between the IL-13 plus 10 mmol/L
pG-2006– and IL-13–treated groups. C, TER kinetics (left panel) and para-
ellular permeability of FITC-dextran (right panel) in bronchial epithelial
ells from asthmatic patients in response to 10 mmol/L CpG-2006. D, Alter-
tion of gene expression of TJ-related molecules in response to 10 mmol/L
pG-2006. Representative data are shown in Fig 1, A-D (n 5 3). u.s., Unsti-









FIG 2. Immunofluorescence detection of claudin-4 (green) and ZO-1 (red) in ALI-cultured bronchial epithe-
lial cells from nonasthmatic (A) and asthmatic (B) subjects. Representative pictures from 3 donors each are
shown. Cells were fixed after 48 hours of stimulation with 10 mmol/L CpG-2006. 49,6-diamidino-2-
phenylindole (DAPI) was used to visualize nuclei. Bar 5 20 mm.
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(see Fig E3 in this article’s Online Repository at www.jacionline.
org), suggesting that the chronic status or severity of the type 2
immune response during inflammation can influence the efficacy
of CpG. Although detailed mechanisms remain to be examined,
IL-13 receptor and TLR9 signals might modulate each other for
barrier integrity.
These findings focused our interest on investigation of whether
CpG-2006 could restore the already impaired barrier of bronchial
epithelial cells from asthmatic patients. We observed that CpG-
2006 stimulation significantly increased the initially low TER and
decreased FITC-dextran flux of bronchial epithelial ALI cultures
from asthmatic patients (Fig 1, C). These results suggest that the
disrupted epithelial barrier in asthmatic patients can be recovered
by TLR9-specific ligands.
Next, we evaluated the expression of TJ-related genes using
quantitative PCR. Expression of claudin-1, claudin-4, claudin-7,
occludin, zonula occludens (ZO)-1, ZO-2, and ZO-3 increased
after CpG-2006 stimulation of ALI-cultured bronchial epithelial
cells from nonasthmatic donors (Fig 1, D, and see Fig E4, A, in
this article’s Online Repository at www.jacionline.org). In
contrast, control DNA did not affect the expression of these genes
(see Fig E4, B).
Because TJ proteins must be correctly assembled into TJ
structures to efficiently contribute to the barrier function of thecells, we investigated the distribution of the TJ-associated
molecule ZO-1 and claudin-4 protein, which is known as a
sealing claudin. CpG-2006–stimulated bronchial epithelial cells
from nonasthmatic donors had higher ZO-1 and claudin-4
immunofluorescence at the cell boundary compared with that in
unstimulated control cells (Fig 2, A, and see Fig E5, A, in this ar-
ticle’s Online Repository at www.jacionline.org). Bronchial
epithelial cells from asthmatic patients showed a constitutive
decrease in claudin-4 and ZO-1 immunofluorescence. CpG-
2006 stimulation remarkably restored the impaired TJ immuno-
staining of bronchial epithelial ALI cultures from asthmatic
patients (Fig 2, B, and see Fig E5, B), which is consistent with
the TER and FITC-dextran flux measurements shown above.
Therefore improvement of the barrier in bronchial epithelial cells
by CpG-2006 seems to be mediated by enhanced expression of
TJ-related molecules and their appropriate distribution on cell-
cell borders.
Rapid increase in the prevalence of asthma over the past
several decades was predominantly attributed to alteration of
environmental factors rather than genetic changes within a few
generations. The hygiene hypothesis explains the increasing
morbidity of allergic inflammation ascribed to less exposure to
bacteria and their products.7 Recent reports revealed the protec-
tive effect of the airway microbiome, a putative source of CpG-
DNA, against allergic airway inflammation.8 Furthermore, it was
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candidate for asthma.9 The induction of TH1 and regulatory
T- and B-cell responses were suggested as immunoprotective
mechanisms.7,10,11 In the present study we demonstrated that
CpG-DNA improved and restored human bronchial barrier integ-
rity through increased expression of TJ-related molecules and
their proper allocation.
In conclusion, these data suggest that administration of CpG-
DNA could be a useful intervention and demonstrate an
additional explanation for the hygiene hypothesis in both the
prevention and treatment of asthma by restoring impaired
epithelial barrier.
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New wheat allergens related to baker’s
asthma
To the Editor:
Baker’s asthma is a serious occupational obstructive airway
disease affecting 4% to 25% of bakery workers worldwide.1
Wheat flour is the primary cereal used in bread baking, and wheat
flour allergy is the leading cause of baker’s asthma.2,3 The
diagnosis of wheat allergy requires the following criteria to be
fulfilled: a clinical history with typical exposure-related
symptoms and confirmation of type I sensitization by skin prick
tests, ImmunoCAP tests, or both and specific inhalation challenge
tests (SICTs) when indicated. The natural origin of the native
flour extracts used for the commercially available skin prick
and ImmunoCAP tests results in batch-to-batch variation, a
limited allergen spectrum, and contamination by other
components. Therefore the test reliability is limited, and a
considerable number of false-negative results with commercial
extracts have been shown.4
Because of these limitations, the gold standard for the diagnosis
of baker’s asthma is still the SICT. However, this test is invasive
and not free of risk. Therefore there is a need to reduce the number
of false-negative results in the diagnosis of wheat sensitization.
Many different wheat allergens are responsible for develop-
ment of wheat flour allergy, as demonstrated by immunoblotting.4
To date, some wheat flour allergens have been described at the
molecular level, such as allergens belonging to the a-amylase in-
hibitor family; acyl-CoA oxidase and fructose-bisphosphate
aldolase, a wheat glycoprotein with peroxidase activity; triose-
phosphate isomerase; thioredoxin; glutathione transferase,
1-Cys-peroxiredoxin; dehydrin; and profilin.4,5 In our previous
work we also identified the relevant wheat allergen Tri a 21, a
water-insoluble ab-gliadin.6 There are 21 wheat allergens (9 of
them are food allergens) registered in the International Union of
Immunological Societies nomenclature, although none of them
have been identified as major allergens. With this lack of major
allergens, there is a need to expand the baker’s allergen panel
by identifying further allergens that can be added to available
diagnostics (ie, by spiking commercial extracts with recombinant
proteins) to improve their sensitivity and specificity.
With the objective of improving the diagnostic tests by
completing the baker’s allergen panel, we aimed to identify and
characterize further wheat allergens associated with baker’s
allergic asthma. For this purpose, we produced recombinant
allergens because they are of great purity and show higher
specificity than native extracts. Sera from 151 bakers with allergic
bronchial asthma caused by a type I IgE–mediated response to
flour dust were used for IgE immunodetection. The diagnosis of
baker’s asthma was made based on a clinical history and
METHODS
Cell cultures and stimulations
Primary human bronchial epithelial cells were purchased from Lonza
(Basel, Switzerland) or obtained from Dr Marek Sanak and Dr Bogdan
Jakiela (Jagiellonian University, Krakow, Poland). All cells lines from
Jagiellonian University were collected after obtaining written informed
consent, and the protocol was approved by the University Bioethical
Committee. Donor information is shown in Table E1. Cells were cultured
as monolayers in bronchial epithelial cell basal medium supplemented
with the SingleQuots Kit (Lonza) at 378C in a humidified atmosphere at
5% CO2. Medium was changed every second day. Cells were seeded at
a density of 1.5 3 105 cells in a 6.5-mm diameter polyester membrane
with a pore size of 0.4 mm (Corning Costar, Corning, NY) in medium, as
previously reported, to develop ALI cultures.E1 After the cells grew to
complete confluence, medium in the apical compartment was removed to
allow the cells to differentiate. Stimulation experiments were initiated
when TER reached a plateau. For cell stimulation, culture media were sup-
plemented with the following reagents: 0.1 to 10 mmol/L CpG-2006 (59-
TCGTCGTTTGTCGTTTTGTCGTT-39; Microsynth GmbH, Balgach,
Switzerland), 10 mmol/L CpG-K3 (59-ATCGACTCTCGAGCGTTCTC-
39), 10 mmol/L CpG-K23 (59-TCGAGCGTTCTC-39; a kind gift from Dr Ih-
san Gursel, Bilkent University, Ankara, Turkey), 1 to 100 mg/mL salmon
spermDNA (InvivoGen, San Diego, Calif), and 10 ng/mL IL-13 (PeproTech,
London, United Kingdom). CpG-2006 at 10 mmol/L is equal to 77 mg/mL
DNA.
TER and paracellular flux measurement
TER and paracellular diffusion of FITC-labeled 4-kDa dextran (Sigma-
Aldrich, St Louis, Mo) were determined as surrogate markers of barrier
integrity. TER was measured at indicated time points before and after
stimulation with a Millicell-ERS Volt-Ohm Meter (Millipore, Temecula,
Calif). Paracellular flux measurements were performed after TER experi-
ments. Paracellular permeability was evaluated 24 hours after apical addition
of 2 mg/mL FITC-dextran based on the intensity of FITC in the basolateral
medium, as determined with an ELISA reader (Mithra LB 940; Berthold
Technologies, Bad Wildbad, Germany) at 480 nm. Each measurement was
carried out in triplicates.
mRNA isolation and RT-PCR
Total RNAwas extracted and purified with an RNeasy Mini Kit (Qiagen,
Hilden, Germany) and RNase-free DNase (Qiagen), according to the
manufacturer’s instructions. Total RNA was reverse transcribed into cDNA
by using a RevertAid RT kit containing random hexamers (Thermo Fisher
Scientific,Woburn,Mass). Quantitative PCRwas performedwith target gene–
specific primers (Microsynth) and SYBR Green PCR Master Mix (Thermo
Fisher Scientific) on an ABI PRISM 7000 Sequence Detection System
(Applied Biosystems, Foster City, Calif), as described in the manufacturer’s
protocol. Sequences of the primers for detecting target gene expression are
listed in Table E2. The amount of elongation factor 1a mRNA was used to
standardize the quantities of each transcript according to the22DDCT value.E2
Immunofluorescence staining of TJs
ALI-cultured cells were fixed with 4% paraformaldehyde (Fluka, Sigma-
Aldrich) and permeabilized with PBS containing 0.1% Triton-X (Acros
Organics, Gell, Belgium) and 0.02% SDS (Sigma-Aldrich). After rinsing
these specimens with PBS, they were incubated with optimally diluted
polyclonal rabbit anti–ZO-1 (Invitrogen, Carlsbad, Calif) at room temperature
for 45 minutes and Alexa Flour 546–labeled goat anti-rabbit antibody
(Invitrogen) and Alexa Flour 488–labeled anti–claudin-4 mAb (clone
3E2C1, Invitrogen) under the same conditions for another 45 minutes. Then
slides were mounted with ProLong-Gold Antifade Reagent (Invitrogen)
containing 49,6-diamidino-2-phenylindole for counterstaining of the cell
nuclei. Specimens were examined under a confocal microscope (Leica TCS
SPE, Leica Microsystems, Heerbrugg, Switzerland). Data were analyzed and
fluorescent intensities were quantified with ImageJ software (National
Institutes of Health, Bethesda, Md).
Statistics
Data analysis was performed with Prism Version 6 software (GraphPad
Software, La Jolla, Calif). Statistical significance was evaluated by using the
2-tailed unpaired Student t test or ANOVAwith Tukey post hoc tests. Graph
bars in the figures present means 6 SD.
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FIG E1. There is no difference in the efficacy of CpG-2006 treatment
between apical and basolateral administration in nonasthmatic bronchial
epithelial cells. TER time kinetics (left panel) and paracellular flux (right
panel)weremeasured. CpG-2006 stimulation was started at t5 0 andmain-
tained until finishing the experiment. CpG-2006 treatment of the ALI from
apical and basolateral administration versus unstimulated control (u.s.):
*P < .05 and **P < .01.
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FIG E2. Role of different CpGs and control DNA in the improvement of barrier integrity. Barrier integrity as
determined by using TER and paracellular flux in response to CpG-K3 (A), CpG-K23 (B), and control DNA (C)
stimulation were determined based on TER (left panels) and FITC-dextran 4-kDa paracelluar flux (right
panels), is shown. Stimulations with CpGs or control DNA were started at t 5 0 and maintained until finish-
ing the experiments. CpG-K3 and CpG-K23 also enhance barrier integrity. Control DNA does not affect TER
or paracellular permeability of FITC-dextran. u.s., Unstimulated. *P < .05 and **P < .01.
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FIG E3. TER kinetics of nonasthmatic bronchial epithelial cells treated with
IL-13 and CpG-2006. IL-13 treatment was started at t5 0, and CpG-2006 was
added at 10 mmol/L after 24, 48, or 72 hours of IL-13 stimulation. All
stimulations were maintained until the end of the experiment. Extended
time exposure to IL-13 abolishes reactivity to CpG. u.s., Unstimulated.
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FIG E4. CpG-DNA enhances mRNA expression of TJs, claudin-1, claudin-4, claudin-7, and occludin, as well
as that of the TJ-associated molecules ZO-1, ZO-2, and ZO-3. The dose-dependent response of mRNA
expression of TJ-related molecules is shown. Bronchial epithelial cells from nonasthmatic subjects were
treated with CpG-2006 (A). Control DNA did not show any effect (B). *P < .05 and **P < .01.
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FIG E5. Relative fluorescence signal intensity of claudin-4 and ZO-1 with or
without CpG-2006 stimulation in bronchial epithelial cells from nonasth-
matic (A) and asthmatic (B) subjects. Each value was calculated after
removing background signal by using ImageJ software. Five different
view fields were compared (n 5 3). *P < .05 and **P < .01.
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TABLE E1. Information of donors used in this study
Donor Asthmatic/nonasthmatic Age (y) Sex Ethnic group
1 Nonasthmatic 67 Male White
2 Nonasthmatic 24 Female White
3 Nonasthmatic 56 Male White
4 Nonasthmatic 56 Female Black
5 Nonasthmatic 44 Female Hispanic
6 Nonasthmatic 42 Male White
7 Asthmatic 54 Male White
8 Asthmatic 15 Female White
9 Asthmatic 25 Male Hispanic
10 Asthmatic 67 Male White
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TABLE E2. Primer sequences for quantitative PCR (indicated as 59-39)
Gene Forward primer Reverse primer
Claudin-1 CAG TCA ATG CCA GGT ACG AAT TT AAG TAG GGC ACC TCC CAG AAG
Claudin-4 TGT ACC AAC TGC CTG GAG GAT GAC ACC GGC ACT ATC ACC ATA A
Claudin-7 GGG CAT GAA GTG CAC GCG CT CGG CAA GAC CTG CCA CGA TG
Occludin GAT GAG CAG CCC CCC AAT GGT GAA GGC ACG TCC TGT GT
ZO-1 ACA GTG CCT AAA GCT ATT CCT GTG A TCG GGA ATG GCT CCT TGA G
ZO-2 CGG TTA AAT ACC GTG AGG CAA A GGG AAC CAC TGG GTG TAA TTC A
ZO-3 TGG AGA GTC CCC GGC TTC GG TCC CTG GGC AAC TCT GAC CGT
EF1a CTG AAC CAT CCA GGC CAA AT GCC GTG TGG CAA TCC AAT
EF1a, Elongation factor 1.
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